Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

This study is testing whether combining two drugs — bicalutamide (a hormone-blocking drug) and abemaciclib (a cell cycle inhibitor) — can treat a specific type of breast cancer called androgen receptor-positive triple-negative breast cancer that cannot be surgically removed or has spread. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with triple-negative breast cancer that tests positive for androgen receptors - Your cancer is inoperable or metastatic - You have received prior treatment and your cancer has progressed **You may NOT be eligible if...** - You have received prior treatment with a CDK4/6 inhibitor or androgen receptor-targeting drug - You have significant heart problems or uncontrolled other cancers - You are pregnant or breastfeeding - You have certain serious infections or autoimmune conditions Talk to your doctor to see if this trial is right for you.